← All 89bio, INC filings

89bio, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

ETNB
89bio, INC
10-Q: 89bio Reports Wider Q2 Loss, Advances MASH Trials
89bio, a clinical-stage biopharmaceutical company, reported a significantly wider net loss in Q2 2025 due to increased R&D and G&A expenses, while advancing its lead MASH and SHTG product candidates.
ETNB
89bio, INC
10-Q: 89bio Reports First Quarter 2025 Financial Results and Provides Business Update
89bio reports its financial results for the first quarter of 2025, highlighting progress in its MASH and SHTG programs and a strong cash position.
ETNB
89bio, INC
10-Q: 89bio Reports Q3 2024 Financial Results, Highlights Clinical Progress
89bio, Inc. released its third quarter 2024 financial results, detailing increased research and development spending and a net loss, while also highlighting progress in its clinical programs.
ETNB
89bio, INC
10-Q: 89bio Reports Second Quarter 2024 Financial Results and Provides Business Update
89bio, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical development and strategic collaborations.
ETNB
89bio, INC
10-Q: 89bio Reports First Quarter 2024 Financial Results and Provides Business Update
89bio, a clinical-stage biopharmaceutical company, announced its first quarter 2024 financial results, highlighting increased R&D spending and progress in clinical trials for pegozafermin.